P2RY12 and neutropenia: Intriguingly, neutropenia has been described as an adverse drug reaction in some patients treated with P2Y12 inhibitors and, vice versa, a small but significant rise in blood neutrophil counts after terminating P2Y12 antagonist therapy has been recorded [62, 75].